

JANUS HENDERSON CAPITAL FUNDS PLC – JANUS HENDERSON
GLOBAL LIFE SCIENCES FUND

A2 USD ISIN IE0009355771

Investment objective


The Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Performance (%)

Returns	Cumulative				Annualised			
	1 Month	3 Month	YTD	1 Year	3 Year	5 Year	10 Year	
A2 USD (Net)	3.68	14.30	6.41	17.01	4.36	9.48	8.60	
Index	2.25	9.64	5.00	14.32	7.88	10.00	8.74	

Cumulative growth - USD

28 Feb 2014 — 29 Feb 2024



Calendar year	2023	2022	2021	2020	2019
A2 USD (Net)	5.44	-4.35	4.72	23.41	27.06
Index	3.76	-5.41	19.80	13.52	23.24

Performance is on a net of fees basis, with gross income reinvested. Source: at 29/02/24. © 2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Past performance does not predict future returns.** Performance/performance target related data will display only where relevant to the share class inception date and annualised target time period. **The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.** Please note index returns are net of tax.

Fund details

Inception date	31 March 2000
Total net assets	\$3.99bn
Category	Equities
Domicile	Ireland
Structure	Irish Investment Company
Base currency	USD
Index	MSCI World Health Care Index
Morningstar sector	Sector Equity Healthcare
SFDR category	Article 8

In accordance with the Sustainable Finance Disclosure Regulation, the Fund is classified as Article 8 and promotes, among other characteristics, environmental and/or social characteristics, and invests in companies with good governance practices.

Share class information

Inception date	31 March 2000
Distribution type	Accumulation
Currency	USD
Minimum initial investment	2,500

Portfolio management

Andy Acker, CFA	Manager since 2007
Daniel Lyons, Ph.D., CFA	Manager since 2023

Ratings

Overall Morningstar Rating™	★★★★★
As of 29/02/2024	

For more information, refer to page 3.

Characteristics

Number of holdings: Equity issues	118
Annual turnover (1yr trailing)	33.52%
Weighted average market cap	167.70bn
Price-to-book ratio	5.19
Price-to-earnings ratio	20.15

Risk statistics (3 years)

	Fund	Index
Beta	0.98	—
Standard deviation	15.28	14.18
Sharpe ratio	0.11	0.36

Top holdings (%)

	Fund
Eli Lilly & Co	6.63
UnitedHealth Group Inc	5.96
Novo Nordisk A/S	4.80
AstraZeneca PLC	3.55
Merck & Co Inc	3.55
AbbVie Inc	3.21
Abbott Laboratories	2.48
Sanofi SA	2.46
Vertex Pharmaceuticals Inc	2.36
Boston Scientific Corp	2.28

References made to individual securities should not constitute or form part of any offer or solicitation to issue, securities mentioned in the report.

Market capitalisation of equity holdings (%)

	Fund	Index
Over \$100B	51.33	63.87
\$50B to \$100B	6.81	14.54
\$10B to \$50B	17.07	19.99
\$5B to \$10B	5.78	1.39
\$1B to \$5B	16.18	0.08
\$500M to \$1B	0.45	—
\$250M to \$500M	0.16	—
N/A	1.63	0.13

Sector allocation (%)

	Fund	Index
Biotechnology	32.49	13.57
Pharmaceuticals	30.57	42.00
Health Care Equipment	14.16	16.07
Managed Health Care	9.58	8.95
Life Sciences Tools & Services	5.78	9.53
Health Care Supplies	2.98	2.81
Health Care Distributors	1.61	2.04
Health Care Facilities	1.26	1.05
Health Care Services	0.80	3.45
Application Software	0.11	—

Top countries/regions (%)

	Fund	Index
United States	78.34	72.47
Denmark	6.22	5.63
United Kingdom	3.55	3.89
Switzerland	3.49	6.97
France	2.46	2.56
Japan	1.67	4.15
China	1.63	—
Netherlands	1.53	0.21
Ireland	0.50	—
Korea, Republic Of	0.04	—

Regions (%)

	Fund	Index
North America	78.35	72.48
Europe	17.75	21.45
Japan	1.67	4.15
Asia/Pacific Ex Japan	1.66	1.73

Codes

ISIN	IE0009355771
Bloomberg	JANGLA1
Cusip	G50110165
SEDOL	0935577

Fees & charges (%)

Annual management charge (AMC) 1.50

Ongoing charge (OCF) 2.40

All ongoing charges stated are as per latest published report and accounts. Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time. For further explanation of charges please visit our Fund Charges page at www.janushenderson.com. Under some circumstances initial charges may apply. Please refer to the Prospectus for more details.

Additional fund information

Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change. As of 31 January 2023, Daniel Lyons Ph.D., CFA also manages this fund. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. This is an Irish Investment Company regulated by the Central Bank of Ireland. Information relating to other currencies and fee structure can be found in the fund prospectus. Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk. Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations. To obtain our prospectus and any additional information please visit our website on: www.janushenderson.com. A short-term trading fee may be applied upon exiting the fund as per the prospectus. Refer to the Annual Report and Accounts for more information on ongoing charges, AMC included. Investment into the fund will acquire units/shares of the fund itself and not the underlying assets owned by the fund. Cash balances and exposures are based on settled and unsettled trades as at the reporting date.

General risks

Past performance does not predict future returns.

The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change.

Fund specific risks

When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies. The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider. Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result. Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses. If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified. The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events. The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations. If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates. Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.

Source for fund ratings/awards

Overall Morningstar Rating™ is a measure of a fund's risk-adjusted return, relative to similar funds. Fund share classes are rated from 1 to 5 stars, with the best performers receiving 5 stars and the worst performers receiving a single star. Overall Morningstar Rating™ is shown for Janus Henderson share classes achieving a rating of 4 or 5. Ratings should not be taken as a recommendation. For more detailed information about Morningstar Ratings, including its methodology, please go to www.global.morningstar.com/managerdisclosures.

Glossary

Beta

Beta measures how a fund or security moves in relationship to the overall market. A market has a beta of 1. If the fund/security's beta is more than 1, it moves more than the market, while a beta lower than 1 means it moves to a lesser extent than the market. A negative beta could mean the fund/security moves in the opposite direction to the market.

Price-to-book (P/B) ratio

A financial ratio used to value a company's shares. It is calculated by dividing a company's market value (share price) by the book value of its equity (value of the company's assets on its balance sheet). A P/B value <1 can indicate a potentially undervalued company or a declining business. The higher the P/B ratio, the higher the premium the market is willing to pay for the company above the book (balance sheet) value of its assets.

Price-to-earnings (P/E) ratio

A popular ratio used to value a company's shares, compared to other stocks, or a benchmark index. It is calculated by dividing the current share price by its earnings per share.

Sharpe ratio

This measures a portfolio's risk-adjusted performance. A high Sharpe ratio indicates a better risk-adjusted return. The ratio is designed to measure how far a portfolio's return can be attributed to fund manager skill as opposed to excessive risk taking.

Standard deviation

A statistic that measures the variation or dispersion of a set of values/data. A low standard deviation shows the values tend to be close to the mean while a high standard deviation indicates the values are more spread out. In terms of valuing investments, standard deviation can provide a gauge of the historical volatility of an investment.

Weighted average market cap

The average market capitalisation of a holding, weighted by the size of that position in a portfolio or index.

FOR MORE INFORMATION PLEASE VISIT JANUSHENDERSON.COM

Janus Henderson
INVESTORS

The content is for information purposes only and should not be used or construed as investment, legal or tax advice, or as an offer to sell, a solicitation of an offer to buy, or a recommendation to buy, sell or hold any security, investment strategy or market sector. Nothing in this material shall be deemed to be a direct or indirect provision of investment management services specific to any client requirement. Opinions and examples are meant as an illustration of broader themes, are not an indication of trading intent, are subject to change and may not reflect the views of others in the organization. It is not intended to indicate or imply that any illustration/example mentioned is now or was ever held in any portfolio. No forecasts can be guaranteed and there is no

guarantee that the information supplied is complete or timely, nor are there any warranties with regard to the results obtained from its use. Janus Henderson is the source of data unless otherwise indicated, and has reasonable belief to rely upon the accuracy and completeness of all information available from public sources. **Past performance does not predict future returns. Investing involves risk, including the possible loss of principal and fluctuation of value.** Not all products or services are available in all jurisdictions. This material or information contained in it may be restricted by law, and may not be reproduced or referred to without express written permission or used in any jurisdiction or circumstance in which its use would be unlawful. Janus Henderson is not responsible for any unlawful distribution of this material to any third parties, in whole or in part. The contents have not been approved or endorsed by any regulatory agency. The value of an investment and the income from it can fall as well as rise and investors may not get back the amount originally invested. There is no assurance stated objective(s) will be met. There is no assurance that the investment process discussed includes an effort to monitor and manage risk which should not be confused with and does not imply low risk or the ability to control certain risk factors. Various account minimums or other eligibility qualifications apply depending on the investment strategy, vehicle of investor jurisdiction. Portfolio holdings are subject to change without notice. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes. Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost.

Note to PRC Readers: Janus Henderson is not licensed, authorised or registered with the China Securities Regulatory Commission for investment management or investment consultancy business or otherwise approved by any PRC regulatory authorities to provide investment management or investment consultancy services in the People's Republic of China (the "PRC") (which, for such purposes, does not include the Hong Kong or Macau Special Administrative Regions or Taiwan). The information contained herein has not been, and will not be, submitted to, reviewed by, approved by, verified by, registered or filed with any PRC regulatory bodies and the use of the content shall be limited to the extent permitted by applicable laws, regulations and relevant requirements. Janus Henderson makes no representation and warranties that it is, and will be, in compliance with PRC laws. Nothing in the information contained herein shall be deemed or construed as providing investment management or investment consultancy services by Janus Henderson in the PRC, nor shall it be will viewed as investment advice in relation to PRC capital markets, securities and mutual funds, which may require Janus Henderson to obtain or be subject to any approval, licensing, filing, registration, or other qualification requirements of the relevant Chinese regulatory authorities. The information contained herein is being provided on a confidential basis solely for the information of those persons to whom it is given. No invitation to offer, or offer for, or sale of, the fund will be made in the PRC whether publicly or non-publicly or by any means under the PRC laws (whether publicly or non-publicly). The information relating to the fund contained in the offering documents has not been, and will not be, submitted to, reviewed by, approved by, verified by, registered or filed with any PRC regulatory bodies. The Fund may only be offered or sold to PRC investors that are authorized to buy and sell securities denominated in foreign exchange. PRC investors are responsible for obtaining all required governmental approvals, permits, verification, licenses and registration (if any) from all competent governmental authorities before purchasing the fund. This document and the information contained in it is only available to institutional investors with QDII licence. Not for public distribution or use in the PRC. This document is provided upon request of duly licensed commercial banks in China under the mechanism of Qualified Domestic Institutional Investors ("QDII Bank") for their QDII products.

Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc. In case of discrepancies between the English and Simplified Chinese versions, the English version shall prevail.